Therapeutic cancer vaccines have proven to seldom induce dramatic clinical response
when used alone, and therefore, they are being studied in combination with additional …

Cancer immunotherapy can induce sustained responses in patients with cancers in a broad
range of tissues, however, these treatments require the optimized combined therapeutic …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

Introduction: Multiple immune checkpoint inhibitors (ICIs) that modulate immune cells in the
periphery and the tumor microenvironment (TME) have been approved, as have the …

Cancer vaccines and immune checkpoint inhibitors (ICIs) function at different stages of the
cancer immune cycle due to their distinct mechanisms of action. Therapeutic cancer …

This comprehensive review delves into the rapidly evolving arena of cancer vaccines.
Initially, we examine the intricate constitution of the tumor microenvironment (TME), a …

Effective treatment of established tumors requires rational multicombination immunotherapy
strategies designed to target all functions of the patient immune system and tumor immune …

Clinical approval of the immune checkpoint blockade (ICB) agents for multiple cancer types
has reinvigorated the long-standing work on cancer vaccines. In the pre-ICB era, clinical …

Therapeutic cancer vaccines have become increasingly qualified for use in personalized
cancer immunotherapy. A deeper understanding of tumor immunology and novel antigen …

Concurrent with US Food and Drug Administration (FDA) approval of the first therapeutic
cancer vaccine, a wide spectrum of other cancer vaccine platforms that target a diverse …